These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
103 related articles for article (PubMed ID: 6616496)
1. Phase II trial of mitoguazone in patients with advanced squamous cell carcinoma of the head and neck. Perry DJ; Crain SM; Weltz MD; Wilson JP; Davis RK; Woolley PV; Forastiere AA; Taylor HG; Weiss RB Cancer Treat Rep; 1983 Jan; 67(1):91-2. PubMed ID: 6616496 [TBL] [Abstract][Full Text] [Related]
2. Phase II trial of mitoguazone in patients with advanced head and neck cancer. Thongprasert S; Bosl GJ; Geller NL; Wittes RE Cancer Treat Rep; 1984 Oct; 68(10):1301-2. PubMed ID: 6525604 [No Abstract] [Full Text] [Related]
3. Mitoguazone in advanced squamous cell carcinoma of head and neck origin: a phase II trial of the Southeastern Cancer Study Group. Luedke DW; Maddox W; Birch R; Velez-Garcia E; Schleuter J Cancer Treat Rep; 1986 Apr; 70(4):529-30. PubMed ID: 3698048 [No Abstract] [Full Text] [Related]
4. [Phase II trial of mitoguazone in patients with recurrent extensive cervicofacial tumors]. Coninx P; Nasca S; Jezekova D; Roelandt H; Morel M; Legros M; Cattan A Bull Cancer; 1985; 72(2):153-4. PubMed ID: 4005436 [No Abstract] [Full Text] [Related]
5. Phase II study of methyl-GAG in the treatment of esophageal carcinoma. Kelsen D; Chapman R; Bains M; Heelan R; Dukeman M; Golbey R Cancer Treat Rep; 1982 Jun; 66(6):1427-9. PubMed ID: 7083245 [TBL] [Abstract][Full Text] [Related]
6. Bioreductive alkylating agent porfiromycin in combination with radiation therapy for the management of squamous cell carcinoma of the head and neck. Haffty BG; Son YH; Wilson LD; Papac R; Fischer D; Rockwell S; Sartorelli AC; Ross D; Sasaki CT; Fischer JJ Radiat Oncol Investig; 1997; 5(5):235-45. PubMed ID: 9372546 [TBL] [Abstract][Full Text] [Related]
7. Phase II trial of methylglyoxal-bis-(guanylhydrazone) in non-small-cell lung cancer. Chapman R; Kelsen D; Gralla R; Itri L; Casper E; Young C; Golbey R Cancer Clin Trials; 1981; 4(4):389-91. PubMed ID: 6274532 [TBL] [Abstract][Full Text] [Related]
8. Aclacinomycin. Phase II evaluation in advanced squamous carcinoma of the head and neck. Kish JA; Al-Sarraf M Am J Clin Oncol; 1984 Oct; 7(5):535-7. PubMed ID: 6507374 [TBL] [Abstract][Full Text] [Related]
9. The evaluation of amifostine for mucosal protection in patients with advanced loco-regional squamous cell carcinomas of the head and neck (SCCHN) treated with concurrent weekly carboplatin, paclitaxel, and daily radiotherapy (RT). Suntharalingam M; Jaboin J; Taylor R; Wolf J; Banglore M; Van Echo D; Ord R Semin Oncol; 2004 Dec; 31(6 Suppl 18):2-7. PubMed ID: 15726515 [TBL] [Abstract][Full Text] [Related]
10. Phase II trial of mitoguazone in patients with relapsed small cell carcinoma of the lung. Scher H; Chapman R; Kelsen D; Gralla R; Wittes R Cancer Treat Rep; 1984 Mar; 68(3):561-2. PubMed ID: 6322989 [No Abstract] [Full Text] [Related]
11. Phase II trial of methyl-G (methylglyoxal bis-guanylhydrazone) in patients with metastatic renal cell carcinoma. Fuks JZ; Van Echo DA; Aisner J; Mitchell EP; Woolley PV; Wiernik PH Cancer Clin Trials; 1981; 4(4):411-4. PubMed ID: 7318123 [TBL] [Abstract][Full Text] [Related]
12. Final report of a phase II evaluation of paclitaxel in patients with advanced squamous cell carcinoma of the head and neck: an Eastern Cooperative Oncology Group trial (PA390). Forastiere AA; Shank D; Neuberg D; Taylor SG; DeConti RC; Adams G Cancer; 1998 Jun; 82(11):2270-4. PubMed ID: 9610709 [TBL] [Abstract][Full Text] [Related]
13. Phase II study of induction and adjuvant chemotherapy for squamous cell carcinoma of the head and neck. A long-term analysis for the Illinois Cancer Center. Athanasiadis I; Taylor S; Vokes EE; Pelzer HJ; Rademaker A; Mittal BB; Ganzenko N; Blough R; Lester EP; Kies MS Cancer; 1997 Feb; 79(3):588-94. PubMed ID: 9028372 [TBL] [Abstract][Full Text] [Related]
14. Mitoguazone in advanced renal carcinoma: a phase II trial of the Southwest Oncology Group. Knight WA; Drelichman A; Fabian C; Bukowski RM Cancer Treat Rep; 1983 Dec; 67(12):1139-40. PubMed ID: 6652631 [No Abstract] [Full Text] [Related]
15. Phase II trial of ICRF-187 in squamous cell carcinoma of the head and neck. Wheeler RH; Bricker LJ; Natale RB; Baker SR Cancer Treat Rep; 1984 Feb; 68(2):427-8. PubMed ID: 6421483 [TBL] [Abstract][Full Text] [Related]
16. Randomized phase III evaluation of cisplatin plus fluorouracil versus cisplatin plus paclitaxel in advanced head and neck cancer (E1395): an intergroup trial of the Eastern Cooperative Oncology Group. Gibson MK; Li Y; Murphy B; Hussain MH; DeConti RC; Ensley J; Forastiere AA; J Clin Oncol; 2005 May; 23(15):3562-7. PubMed ID: 15908667 [TBL] [Abstract][Full Text] [Related]
17. Phase II trial of 4'-epi-doxorubicin in advanced carcinoma of head and neck origin. Magee MJ; Howard J; Bosl GJ; Wittes RE Cancer Treat Rep; 1985 Jan; 69(1):125-6. PubMed ID: 3855384 [TBL] [Abstract][Full Text] [Related]
18. Methyl-GAG in patients with malignant neoplasms: a phase I re-evaluation. Hart RD; Ohnuma T; Holland JF; Bruckner H Cancer Treat Rep; 1982 Jan; 66(1):65-71. PubMed ID: 7053268 [TBL] [Abstract][Full Text] [Related]
19. Phase II trial of mitogauzone in malignant primary brain tumors. Feun LG; Yung WK; Stewart DJ; Savaraj N; Bodey GP Cancer Treat Rep; 1985 Mar; 69(3):329-30. PubMed ID: 3978660 [TBL] [Abstract][Full Text] [Related]
20. Phase II evaluation of methyl-GAG in patients with refractory metastatic breast cancer. Yap HY; Blumenschein GR; Schell F; Bodey GP Cancer Treat Rep; 1981; 65(5-6):465-7. PubMed ID: 7237467 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]